MCID: THR024
MIFTS: 56

Thrombosis

Categories: Blood diseases, Cardiovascular diseases

Aliases & Classifications for Thrombosis

MalaCards integrated aliases for Thrombosis:

Name: Thrombosis 12 29 54 43 15 71
Thrombosis of Blood Vessel 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0060903
MeSH 43 D013927
UMLS 71 C0040053 C2586211

Summaries for Thrombosis

Disease Ontology : 12 A vascular disease caused by the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system.

MalaCards based summary : Thrombosis, also known as thrombosis of blood vessel, is related to portal vein thrombosis and cavernous sinus thrombosis. An important gene associated with Thrombosis is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Collagen chain trimerization and Response to elevated platelet cytosolic Ca2+. The drugs Alprostadil and Nicorandil have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and testes, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 74 Thrombosis (from Ancient Greek ????????? thrombosis "clotting") is the formation of a blood clot inside... more...

Related Diseases for Thrombosis

Diseases related to Thrombosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2021)
# Related Disease Score Top Affiliating Genes
1 portal vein thrombosis 35.0 SERPINC1 PROC PLAT MTHFR JAK2 F5
2 cavernous sinus thrombosis 35.0 SERPINC1 F2
3 coronary thrombosis 34.9 VWF SERPINC1 PLAT GP1BA F3
4 intracranial thrombosis 34.8 VWF SERPINC1 PLAT MTHFR F5 F3
5 sagittal sinus thrombosis 34.8 SERPINC1 F5 F3 F2
6 lateral sinus thrombosis 34.8 SERPINC1 MTHFR F2
7 carotid artery thrombosis 34.7 VWF SERPINC1 PLAT F3
8 intracranial sinus thrombosis 34.6 SERPINC1 MTHFR F3 F2
9 cerebral sinovenous thrombosis 34.6 PROS1 MTHFR F5 F3 F2 APOH
10 thrombophilia due to thrombin defect 34.3 THBD SERPINC1 PROC PLAT MTHFR F5
11 budd-chiari syndrome 34.2 SERPINC1 MTHFR JAK2 FGB F5 F3
12 heparin-induced thrombocytopenia 33.7 SERPINC1 F3
13 antithrombin iii deficiency 33.6 SERPINC1 MTHFR JAK2 F5 F2 APOH
14 antiphospholipid syndrome 33.5 VWF THBD SERPINC1 PLAT MTHFR F5
15 post-thrombotic syndrome 33.5 SERPINC1 PLAT F5 F3 F2
16 paroxysmal nocturnal hemoglobinuria 33.4 THBD SERPINC1 F2 CD55
17 thoracic outlet syndrome 33.4 SERPINC1 PLAT F2
18 factor v leiden thrombophilia 33.4 MTHFR F5
19 prothrombin-related thrombophilia 33.4 MTHFR F2 F13A1
20 protein s deficiency 33.4 THBD SERPINC1 PROS1 PROC MTHFR F5
21 polycythemia vera 33.3 VWF THBD JAK2 F5 F2
22 hepatic veno-occlusive disease 33.3 THBD SERPINC1 PLAT F3
23 protein c deficiency 33.3 THBD SERPINC1 PROC MTHFR HRG F9
24 essential thrombocythemia 33.2 VWF THBD SERPINC1 MTHFR JAK2 GP1BA
25 may-thurner syndrome 33.2 F5 APOH
26 shwartzman phenomenon 33.2 SERPINA10 F3
27 chronic venous insufficiency 33.2 PLAT MTHFR F2
28 thrombophilia due to activated protein c resistance 33.2 VWF THBD SERPINC1 PLAT MTHFR F9
29 homocysteinemia 33.1 VWF THBD SERPINC1 MTHFR F5 F2
30 buerger disease 33.1 MTHFR F2 APOH
31 factor vii deficiency 33.1 SERPINC1 F9 F3 F2
32 pulmonary embolism 33.0 VWF THBD SERPINC1 PROS1 PROC PLAT
33 dysfibrinogenemia, congenital 33.0 THBD SERPIND1 SERPINC1 PLAT FGB F5
34 factor v deficiency 33.0 VWF F9 F5 F3 F2
35 factor xii deficiency 33.0 VWF SERPINC1 F9 F5 F3 APOH
36 moyamoya disease 1 33.0 VWF SERPINC1 MTHFR F3 F2
37 afibrinogenemia, congenital 32.9 VWF SERPINC1 PLAT FGB F5 F3
38 cardiovascular system disease 32.9 VWF THBD SERPINC1 PLAT MTHFR F3
39 vascular disease 32.8 VWF THBD SERPINC1 PLAT MTHFR GP1BA
40 thrombophilia 32.8 VWF THBD SERPIND1 SERPINC1 SERPINA10 PROS1
41 systemic lupus erythematosus 32.7 VWF THBD JAK2 F3 F2 CD55
42 stroke, ischemic 32.2 VWF THBD SERPIND1 SERPINC1 PLAT MTHFR
43 portal hypertension 32.1 VWF JAK2 F3 F2
44 varicose veins 32.1 VWF THBD SERPINC1 PLAT MTHFR F5
45 thrombocytopenia 31.9 VWF THBD SERPINC1 PLAT JAK2 GP1BA
46 atherosclerosis susceptibility 31.9 VWF THBD PLAT MTHFR F3
47 intracranial hypertension 31.8 SERPINC1 MTHFR F9 F5 F3 F2
48 venous insufficiency 31.8 VWF PLAT MTHFR F5 F2
49 intermediate coronary syndrome 31.8 VWF SERPINC1 PLAT F3
50 papilledema 31.8 SERPINC1 F3 F2 APOH

Graphical network of the top 20 diseases related to Thrombosis:



Diseases related to Thrombosis

Symptoms & Phenotypes for Thrombosis

MGI Mouse Phenotypes related to Thrombosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.31 F13A1 F2 F3 F5 F9 FGB
2 homeostasis/metabolism MP:0005376 10.28 APOH F13A1 F2 F3 F5 F9
3 hematopoietic system MP:0005397 10.21 CD55 F13A1 F2 F3 F9 GP1BA
4 mortality/aging MP:0010768 10.09 APOH F13A1 F2 F3 F5 F9
5 embryo MP:0005380 10.06 F2 F3 F5 F9 FGB JAK2
6 liver/biliary system MP:0005370 9.86 F5 F9 JAK2 MTHFR PROC PROS1
7 nervous system MP:0003631 9.7 F2 F3 F5 MTHFR PLAT PROC
8 respiratory system MP:0005388 9.17 F13A1 F2 F3 JAK2 PLAT PROC

Drugs & Therapeutics for Thrombosis

Drugs for Thrombosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 844)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
2
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
3
Phenobarbital Approved, Investigational Phase 4 50-06-6 4763
4
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
5
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
6
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
7
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
8
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
9
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
10
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
11
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
12
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
13
Diltiazem Approved, Investigational Phase 4 42399-41-7 39186
14
Nadroparin Approved, Investigational Phase 4
15
Sodium citrate Approved, Investigational Phase 4 68-04-2
16
Pancrelipase Approved, Investigational Phase 4 53608-75-6
17
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767
18
Liraglutide Approved Phase 4 204656-20-2 44147092
19 Orange Approved Phase 4
20
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
21
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
22
Glimepiride Approved Phase 4 93479-97-1 3476
23 Nutmeg Approved Phase 4
24
Fenofibrate Approved Phase 4 49562-28-9 3339
25
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
26
Ezetimibe Approved Phase 4 163222-33-1 150311
27 fluindione Approved, Investigational Phase 4 957-56-2
28
Pravastatin Approved Phase 4 81093-37-0 54687
29
Morphine Approved, Investigational Phase 4 57-27-2 5288826
30
Ranibizumab Approved Phase 4 347396-82-1 459903
31
Zoledronic Acid Approved Phase 4 118072-93-8 68740
32
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
33
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
34
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
35
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
36
Phenindione Approved, Investigational Phase 4 83-12-5 4760
37
acetic acid Approved Phase 4 64-19-7 176
38
Repaglinide Approved, Investigational Phase 4 135062-02-1 65981
39
Gliclazide Approved Phase 4 21187-98-4 3475
40
Canagliflozin Approved Phase 4 842133-18-0
41
Betrixaban Approved, Investigational Phase 4 330942-05-7
42
Propranolol Approved, Investigational Phase 4 525-66-6 4946
43 Taurolidine Approved, Investigational Phase 4 19388-87-5
44
Cobalt Approved, Experimental Phase 4 7440-48-4 104729
45
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
46
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
47
Salmon Calcitonin Approved, Investigational Phase 4 47931-85-1 16129616
48
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
49
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
50
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0

Interventional clinical trials:

(show top 50) (show all 3043)
# Name Status NCT ID Phase Drugs
1 Study of the OmniWave Endovascular System in Subjects With Lower and Upper Extremity Deep Vein Thrombosis - SONIC I Study Unknown status NCT00640731 Phase 4
2 Outcome of Percutaneous Mechanical Thrombectomy to Treat Acute Deep Venous Thrombosis Unknown status NCT02959801 Phase 4
3 Impact of a Biological Glue (Evicel®) on the Peri Operative Bleeding in Total Knee Prothesis Surgery Unknown status NCT00983112 Phase 4 Human Fibrinogen and human thrombin (Evicel);Sodium Chlorure (Physiological saline)
4 Rosuvastatin for Prevention of Deep Vein Thrombosis in Patients Undergoing Total Knee Replacement Arthroplasty: STOP DVT - A Prospective Randomized Controlled Trial Unknown status NCT01021488 Phase 4 Rosuvastatin 20mg/d for 14days;enoxaparin only
5 A Zelen-design Randomized Controlled Trial of the Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis Unknown status NCT02398357 Phase 4 Nadroparin Calcium and Warfarin
6 Phase 4 Study of Postoperative Prostaglandin E1 in Head and Neck Microsurgery Unknown status NCT00733434 Phase 4 Prostaglandin E1
7 Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis (TWISTER) Unknown status NCT01252420 Phase 4 Enoxaparin
8 Reload of High Dose Atorvastatin for Preventing Deep Vein Thrombosis in Statin Users Undergoing Total Knee Replacement Arthroplasty: RE-STOP-DVT Study- A Prospective Randomized Controlled Trial Unknown status NCT01063426 Phase 4 High dose Atorvastatin+enoxaparin;Enoxaparin
9 Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis:A Zelen-design Multicenter Randomized Controlled Trial Unknown status NCT02630095 Phase 4 Nadroparin Calcium and Warfarin
10 Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography Unknown status NCT02826200 Phase 4 Acenocoumarol
11 PPARGC1β And CNTN4 Genotype as a Pharmacogenetic Assay of Thrombosis and Bleeding Risks - a Cross-Over Controlled Trial of Aspirin in Individuals at Increased Cardiovascular Risk. Unknown status NCT02970604 Phase 4 Aspirin
12 RCT Research: the Treatment of Hepatic Carcinoma With Portal Vein Branch Tumor Thrombosis (Resection or Sorafenib) Unknown status NCT03178656 Phase 4 Sorafenib
13 Randomized-Double Blind Trial to Assess the Incidence and Clinical Relevance of Heparin-Induced Thrombocytopenia (HIT) Antibodies in Trauma Patients Treated With Unfractionated or Low-Molecular Weight Heparin, the HIT-TRAP Trial Unknown status NCT00196417 Phase 4 Standard heparin (UFH) versus certoparin (LMWH)
14 Comparison of Ultra-low-dose Oral Versus Trans-dermal Hormone Therapy on Coagulation Activation and Metabolic Risk Factors for Cardiovascular Disease Unknown status NCT02264743 Phase 4 Femoston Conti;EVOREL® CONTI
15 Late Incomplete Stent Apposition Evaluation II: Vascular Effects Evaluation After Polimer and No-polimer Based Coronary Artery Drug Eluting Stent Ilmplantation. An IVUS Based Study Unknown status NCT01375855 Phase 4
16 Residual Vein Thrombosis Establishes the Optimal Duration of Low Molecular Weight Heparins in Cancer Patients With Deep Vein Thrombosis of the Lower Limbs Unknown status NCT00450645 Phase 4 low molecular weight heparin
17 Low Molecular Weight Heparin in Prevention of Recurrent Arteriovenous Graft Thrombosis in Chronic Hemodialysis Patients. Unknown status NCT01970280 Phase 4 Enoxaparin
18 Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease Unknown status NCT01418794 Phase 4
19 Clinical Evaluation of the Momo Cobalt-Chromium Coronary Stent System for the Treatment of Patients With Coronary Artery Disease Unknown status NCT01535625 Phase 4
20 a Comparative Study of Aspirin Either at Fixed Dose or at a Dose Titrated by Platlet Function Analyzer(PFA-100) vs Placebo in Primary Prevention of Vascular Access for Hemodialysis Unknown status NCT02055131 Phase 4 aspirin
21 Efficacy Study of Nicorandil on Neointima After Coronary Drug-eluting Stent Implantation in Patients With Diabetic Mellitus Unknown status NCT02328521 Phase 4 Nicorandil;nicorandil placebo
22 RANDOMIZED TRIAL OF ZOTAROLIMUS- AND EVEROLIMUS-ELUTING STENTS REGARDING STENT COVERAGE ASSESSED BY OCT Unknown status NCT01230723 Phase 4
23 Prolonged Hemodialysis Catheter Survival With Copolymer Coating and Rt-PA - PROCOPrt-PA Trial Unknown status NCT01670474 Phase 4 rt-PA (2mg/2mL) actilysis;rt-PA
24 The Changes of Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives With Antiandrogenic Activity, Correction by Antioxidants Unknown status NCT02027337 Phase 4 20 mcg ethinylestradiol /3 mg drospirenone;20 mcg ethinylestradiol/3 mg drospirenone and Selmevit;30 mcg ethinylestradiol/3 mg drospirenone;30 mcg ethinylestradiol/3 mg drospirenone and Selmevit;35 mcg ethinylestradiol/2 mg cyproterone;35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
25 Prevención de Parto Prematuro en Gemelares: Ensayo Aleatorio Con Progesterona Vaginal. Unknown status NCT01927029 Phase 4 Progesterone;Placebo
26 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
27 A Clinical Evaluation of Dual Antiplatelet Therapy Duration Following Treatment With the Medtronic Endeavor Zotarolimus-eluting Coronary Stent Unknown status NCT00963781 Phase 4 Reduced duration (6 months) DAPT
28 Twelve Versus 24 Months of Dual Antiplatelet Therapy in Patients With Percutaneous Coronary Intervention for In-stent Restenosis Unknown status NCT02402491 Phase 4 12 months of P2Y12 receptor antagonist;24 months of P2Y12 receptor antagonist;Aspirin
29 Pilop Trial of OCT-determined Coverage of Permanent or Polymer-free Sirolimus Eluting Stent at Long Term Unknown status NCT01260558 Phase 4
30 Randomized Trial of Prasugrel Plus Bivalirudin vs. Clopidogrel Plus Heparin in Patients With Acute STEMI Unknown status NCT00976092 Phase 4 Prasugrel;Bivalirudin;Clopidogrel;Heparin
31 Evaluation of the Potential Action of Coagulation Factors Concentrates in the Reversal of the Antithrombotic Action of New Oral Anticoagulants: Studies ex Vivo in Blood Samples From Healthy Volunteers Unknown status NCT01478282 Phase 4 Rivaroxaban;Dabigatran
32 Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions Unknown status NCT00698607 Phase 4 6-month clopidogrel therapy;12-month clopidogrel therapy
33 Platelet Function With New Pediatric Oxygenator and Heparin and Non Heparin Coating in Pediatric Cardiac Surgery Unknown status NCT01648712 Phase 4
34 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
35 The Effect of Tranexamic Acid (TXA) on Blood Loss in Burn Surgery - A Randomized, Double-Blinded Placebo-Controlled Trial Unknown status NCT03113253 Phase 4 Tranexamic Acid;Placebo
36 Erythropoietin Prevention Trial of Coronary Restenosis and Cardiac Remodeling After Acute Myocardial Infarction (EPOC-AMI) Unknown status NCT00423020 Phase 4 Erythropoietin
37 Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization. Unknown status NCT02099617 Phase 4
38 TITANIC-XV Trial: Prospective, Multicenter and Randomized Trial (Bioactive Bare Metal Titanium Stent Versus Everolimus Drug Eluting Stent) Unknown status NCT01510509 Phase 4
39 Local Delivery of thrombolytIcs Before Thrombectomy in patientS With ST-elevatiOn myocardiaL Infarction Undergoing Primary percuTaneous Coronary interventION - The DISSOLUTION Randomized Trial Unknown status NCT01568931 Phase 4 Urokinase;Saline
40 The Use of Dabigatran Etexilate in Patients With Atrial Fibrillation After Mitral Valve Prosthetic Replacement Unknown status NCT03183843 Phase 4 Dabigatran Etexilate;Warfarin
41 The Efficacy and Safety of Paclitaxel-eluting SeQuent Please Drug-Eluting Balloon for Treatment of lesiOns in Native smalL coronarY Arteries (DEB-ONLY) Unknown status NCT01903902 Phase 4
42 A Prospective, Multicenter, Randomized, Open-label Trial to Evaluate Efficacy and Safety of 5mg Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome Who Underwent Percutaneous Coronary Intervention With BiomatrixTM Stent Unknown status NCT02446730 Phase 4 Prasugel;Clopidogrel
43 Thrombus Aspiration During Percutaneous Coronary Intervention in Acute Non-ST-elevation Myocardial Infarction Study (TAPAS II) Unknown status NCT01013038 Phase 4
44 Test of Efficacy and Safety of the Dual Antiplatelet Therapy Compared to the Combination of Oral Anticoagulant Therapy + Dual Antiplatelet Therapy in Patients With Atrial Fibrillation With Low-moderate Risk Submitted to Coronary Stent Implantation Unknown status NCT01141153 Phase 4 Acetylsalicylic Acid + clopidogrel + acenocoumarol;Acetylsalicylic Acid + clopidogrel
45 Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents. Short Title: Scripps V Unknown status NCT00714545 Phase 4
46 Single-center Randomized Controlled Study of Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Randomized Controlled Trials Unknown status NCT01735227 Phase 4 omeprazole;Pantoprazole
47 Safety and Efficacy of Thrombus Aspiration in Patients With ST-segment Elevation Myocardial Infarction (STEMI) Unknown status NCT02606435 Phase 4
48 Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome Unknown status NCT01951001 Phase 4 Prasugrel
49 Low Dose Rt-PA Plus LMWH Compared With LMWH Alone for the Treatment of Normotensive Pulmonary Embolism Patients With Acute RV Dysfunction: A Randomized,Multi-Center,Controlled Trial Unknown status NCT01531829 Phase 4 Recombinant tissue plasminogen activator (rt-PA);Low Molecular Weight Heparin
50 Comparison of Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI Undergoing PPCI Evaluated by SPECT Unknown status NCT02233790 Phase 4 Ticagrelor;Clopidogrel

Search NIH Clinical Center for Thrombosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Pentoxifylline

Cochrane evidence based reviews: thrombosis

Genetic Tests for Thrombosis

Genetic tests related to Thrombosis:

# Genetic test Affiliating Genes
1 Thrombosis 29

Anatomical Context for Thrombosis

MalaCards organs/tissues related to Thrombosis:

40
Liver, Heart, Testes, Endothelial, Brain, Kidney, Lung

Publications for Thrombosis

Articles related to Thrombosis:

(show top 50) (show all 31237)
# Title Authors PMID Year
1
Acute mesenteric and aortic thrombosis associated with antithrombin deficiency: a rare occurrence. 54 61
19932950 2010
2
The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. 54 61
20353989 2010
3
Persistency of low levels of anticardiolipin and anti-beta2 glycoprotein1 in thrombosis. 54 61
20206880 2010
4
[Relationship of von Willebrand factor gene single-nucleotide polymorphism with thrombosis diseases]. 54 61
20416208 2010
5
Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis. 54 61
20004006 2010
6
Emerging roles of fibronectin in thrombosis. 54 61
20116835 2010
7
An approach to molecular imaging of atherosclerosis, thrombosis, and vascular inflammation using microparticles of iron oxide. 54 61
19883911 2010
8
Neuropilin-1 targeting photosensitization-induced early stages of thrombosis via tissue factor release. 54 61
20087632 2010
9
Continuous intraarterial thrombolysis for early hepatic artery thrombosis following liver transplantation: case report. 54 61
20034941 2010
10
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. 54 61
19582452 2010
11
Low level of factor V is associated with development of deep-vein thrombosis in Japanese patients. 54 61
19497612 2010
12
Murine strain differences in hemostasis and thrombosis and tissue factor pathway inhibitor. 54 61
19398123 2010
13
JAK2 mutation and thrombosis in the myeloproliferative neoplasms. 54 61
20425393 2010
14
ABO blood groups and genetic risk factors for thrombosis in Croatian population. 54 61
20017223 2009
15
Thrombosis markers in hip versus knee arthroplasty: a pilot study. 54 61
20065366 2009
16
Prevalence of factor V leiden mutation in patients with thrombosis in Tunisia. 54 61
20218141 2009
17
[Effects of sodium ozagrel in primary thrombocytosis combined with thrombosis]. 54 61
19840484 2009
18
Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms. 54 61
19214510 2009
19
Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia. 54 61
19195685 2009
20
Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. 54 61
19660606 2009
21
Factor V Leiden and thrombosis in patients with systemic lupus erythematosus: a meta-analysis. 54 61
19421222 2009
22
Locally applied recombinant plasmin results in effective thrombolysis in a porcine model of arteriovenous graft thrombosis. 54 61
19481472 2009
23
Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. 54 61
19414836 2009
24
Autoantibodies to heat shock protein 60 promote thrombus formation in a murine model of arterial thrombosis. 54 61
19192108 2009
25
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. 54 61
19193675 2009
26
The prevalence of factor V (G1691A), MTHFR (C677T) and PT (G20210A) gene mutations in arterial thrombosis. 54 61
19353312 2009
27
Catheter-related thrombosis: biological and clinical evidence for risk with currently available anticoagulants. 54 61
19117960 2009
28
Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura. 54 61
19180123 2009
29
Role of pulsatile perfusion with tissue plasminogen activator in deceased donor kidneys with extensive glomerular thrombosis. 54 61
19249467 2009
30
Mitogen-activated protein kinases in hemostasis and thrombosis. 54 61
18826389 2008
31
Antithrombin level and circuit thrombosis during hemofiltration after cardiopulmonary bypass. 54 61
18575842 2008
32
Acute left atrial thrombosis during anticoagulant therapy in a patient with antithrombin deficiency. 54 61
19014009 2008
33
Role of the protein C pathway in the extraintestinal thrombosis associated with murine colitis. 54 61
18514072 2008
34
Acute effects of different alcoholic beverages on vascular endothelium, inflammatory markers and thrombosis fibrinolysis system. 54 61
18295937 2008
35
Cyclooxygenase-2-linked attenuation of hypoxia-induced pulmonary hypertension and intravascular thrombosis. 54 61
18375790 2008
36
Heparin induced thrombocytopenia with thrombosis: a two step process? 54 61
18702877 2008
37
The paradoxical association between inherited factor VII deficiency and venous thrombosis. 54 61
18282149 2008
38
High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden. 54 61
18616871 2008
39
Arterial thrombosis associated with factor V Leiden and methylenetetrahydrofolate reductase C677T mutation in childhood membranous glomerulonephritis. 54 61
18030499 2008
40
Platelet PlA2 Polymorphism and the risk for thrombosis in heparin-induced thrombocytopenia. 54 61
18208809 2008
41
Platelet collagen receptors, signaling and antagonism: emerging approaches for the prevention of intravascular thrombosis. 54 61
18045662 2008
42
Impaired binding of thrombin to thrombomodulin is associated with risk of deep vein thrombosis. 54 61
18590927 2008
43
A fulminant case of renal vein thrombosis in a patient with autoimmune disorder and membranous nephropathy. 54 61
18480584 2008
44
Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. 54 61
17261530 2007
45
Hyperhomocysteinemia, deep vein thrombosis and vitamin B12 deficiency in a metformin-treated diabetic patient. 54 61
17908667 2007
46
Plasminogen activator inhibitor-1 in vascular thrombosis. 54 61
17896948 2007
47
Late drug-eluting stent thrombosis and erythropoietin: cause and effect? 54 61
17446131 2007
48
Combined effects of thrombosis pathway gene variants predict cardiovascular events. 54 61
17677000 2007
49
Lupus anticoagulant activity as a thrombosis risk factor in lung adenocarcinoma patients. 54 61
17804532 2007
50
Risk of vascular access thrombosis in patients with systemic lupus erythematosus on hemodialysis. 54 61
17534796 2007

Variations for Thrombosis

Expression for Thrombosis

Search GEO for disease gene expression data for Thrombosis.

Pathways for Thrombosis

Pathways related to Thrombosis according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.68 THBD SERPINC1 PROS1 PROC FGB F9
2
Show member pathways
12.63 VWF THBD SERPIND1 SERPINC1 PROS1 PROC
3
Show member pathways
12.2 VWF THBD SERPIND1 SERPINC1 PROS1 PROC
4
Show member pathways
12.03 THBD PROS1 PROC F2
5 11.96 VWF THBD SERPIND1 SERPINC1 PROS1 PROC
6 11.83 VWF GP1BA FGB F2
7
Show member pathways
11.74 PROS1 PROC F9 F2
8 11.71 THBD JAK2 F3
9
Show member pathways
11.66 VWF GP1BA FGB F2
10 11.34 VWF FGB F2
11 10.8 PROS1 PROC F9 F2
12 10.64 VWF GP1BA
13 10.62 PLAT HRG
14 10.49 VWF GP1BA

GO Terms for Thrombosis

Cellular components related to Thrombosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10.13 VWF SERPIND1 SERPINC1 SERPINA10 PROS1 PLAT
2 cell surface GO:0009986 10.03 THBD PLAT HRG GP1BA FGB F3
3 extracellular space GO:0005615 10 THBD SERPIND1 SERPINC1 SERPINA10 PROS1 PROC
4 endoplasmic reticulum lumen GO:0005788 9.95 SERPIND1 SERPINC1 SERPINA10 PROC F9 F5
5 extracellular region GO:0005576 9.86 VWF SERPIND1 SERPINC1 SERPINA10 PROS1 PROC
6 blood microparticle GO:0072562 9.85 SERPINC1 PROS1 HRG FGB F2 F13A1
7 Golgi lumen GO:0005796 9.78 PROS1 PROC F9 F2
8 platelet alpha granule lumen GO:0031093 9.73 VWF PROS1 HRG FGB F5 F13A1
9 platelet alpha granule GO:0031091 9.63 VWF FGB F5
10 collagen-containing extracellular matrix GO:0062023 9.32 VWF SERPINC1 PLAT HRG FGB F9

Biological processes related to Thrombosis according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.95 SERPIND1 SERPINC1 SERPINA10 PROC F5 F2
2 post-translational protein modification GO:0043687 9.93 SERPIND1 SERPINC1 SERPINA10 PROC F5
3 ER to Golgi vesicle-mediated transport GO:0006888 9.93 PROS1 PROC F9 F5 F2 CD55
4 negative regulation of endopeptidase activity GO:0010951 9.92 SERPIND1 SERPINC1 SERPINA10 PROS1 HRG
5 platelet degranulation GO:0002576 9.91 VWF PROS1 HRG FGB F5 F13A1
6 platelet activation GO:0030168 9.89 VWF HRG GP1BA FGB F2
7 hemostasis GO:0007599 9.83 VWF THBD SERPIND1 SERPINC1 SERPINA10 PROS1
8 negative regulation of blood coagulation GO:0030195 9.73 THBD PROS1 PROC APOH
9 blood coagulation, intrinsic pathway GO:0007597 9.72 VWF GP1BA F9 F2 APOH
10 negative regulation of fibrinolysis GO:0051918 9.71 THBD HRG F2 APOH
11 plasminogen activation GO:0031639 9.69 PLAT FGB APOH
12 regulation of blood coagulation GO:0030193 9.65 SERPINC1 HRG GP1BA F2 APOH
13 fibrinolysis GO:0042730 9.63 PROS1 PLAT HRG GP1BA FGB F2
14 positive regulation of blood coagulation GO:0030194 9.57 F2 APOH
15 negative regulation of platelet activation GO:0010544 9.56 THBD F2
16 blood coagulation, fibrin clot formation GO:0072378 9.55 FGB F13A1
17 blood coagulation GO:0007596 9.55 VWF THBD SERPIND1 SERPINC1 SERPINA10 PROS1

Molecular functions related to Thrombosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.77 PLAT JAK2 HRG FGB F2
2 serine-type peptidase activity GO:0008236 9.62 PROC PLAT F9 F2
3 protease binding GO:0002020 9.58 VWF SERPINC1 F3
4 serine-type endopeptidase inhibitor activity GO:0004867 9.46 SERPIND1 SERPINC1 SERPINA10 HRG
5 serine-type endopeptidase activity GO:0004252 9.35 PROC PLAT F9 F3 F2
6 immunoglobulin binding GO:0019865 9.26 VWF HRG
7 heparin binding GO:0008201 9.1 SERPIND1 SERPINC1 SERPINA10 HRG F2 APOH

Sources for Thrombosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....